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Abstract: Norovirus (NoV) genotype GII.4 is responsible for the majority of NoV infections causing
pandemics every few years. A NoV virus-like particle (VLP)-based vaccine should optimally cover the
high antigenic variation within the GII.4 genotype. We compared the immune responses generated
by VLPs of the ancestral GII.4 1999 strain (GII.4 1995/96 US variant) and the most recent GII.4 Sydney
2012 pandemic strains in mice. No significant differences were observed in the type-specific responses
but GII.4 1999 VLPs were more potent in inducing high-avidity antibodies with better cross-reactivity.
GII.4 1999 immune sera blocked binding of GII.4 2006 and GII.4 2012 VLPs to the putative receptors
in a surrogate neutralization assay, whereas GII.4 2012 immune sera only had low blocking activity
against GII.4 2006 VLPs. Amino acid substitution in the NERK motif (amino acids 310, 316, 484,
and 493, respectively), altering the access to conserved blocking epitope F, moderately improved the
cross-blocking responses against mutated GII.4 2012 VLPs (D310N). NoV GII.4 1999 VLPs, uptaken
and processed by antigen-presenting cells, induced stronger interferon gamma (IFN-γ) production
from mice splenocytes than GII.4 2012 VLPs. These results support the use of GII.4 1999 VLPs as a
major component of a NoV vaccine.
Keywords: norovirus; ancestor; variant; GII.4; immune responses; cross-reactivity; blocking
antibodies; NERK motif
1. Introduction
Norovirus (NoV) GII.4 is the predominating NoV genotype, causing up to 85% of acute
gastroenteritis outbreaks of NoV and sporadic infections worldwide [1]. It is associated with more
severe clinical manifestations than other NoV genotypes [2,3]. NoV genogroup II (GII) and GI together
comprise of over 28 genetically divergent NoV genotypes infecting humans [4]. The predominance of
GII.4 for over two decades is associated with several factors including fast replication and effective
person-to-person transmission rates [5,6]. In addition, GII.4 variants recognize a wide range of mucosal
polysaccharides [7] and histo-blood group antigens (HBGAs), which are thought to facilitate NoV
entry and/or infection [8,9].
The NoV particle consists of 90 dimers of capsid VP1 protein organized in T = 3 icosahedral
symmetry [10]. VP1 is divided into two main domains: the shell (S) and the protruding (P) domains,
the latter of which is further subdivided into P1 and P2 domains [10]. The outermost P2 domain
contains the conserved HBGA binding sites but the regions surrounding these sites are evolving due to
constant immune pressure [11]. NoV vaccine development is largely based on NoV virus-like particles
(VLPs) [12–14], antigenically identical to the virus particle, despite recent progress in cultivating NoV
in vitro [15].
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GII.4 NoV undergoes epochal evolution similar to influenza virus; periods of stasis lead into rapid
antigenic drift in common structural epitopes that are under immune pressure [16,17]. NoV-specific
serum antibodies that block binding of NoV VLPs to HBGAs in a surrogate neutralization assay are the
best correlate of protection identified so far [18–20]. Antigenic drift driven by these antibodies can lead
the evolving strains gaining new HBGA binding abilities and/or escaping from previously gained
immunity [21–23]. There are at least six (A–F) evolving “blocking epitopes” described [21,23–25]
and the emergence of a new GII.4 pandemic strain is typically associated with mutations in these
epitopes [23,24,26]. Since the 1990s seven pandemics have been caused by GII.4 variants: Grimsby
(1995/96 US), Farmington Hills (2002), Hunter (2004), Yerseke (2006a), Den Haag (2006b), New Orleans
(NO, 2009), and Sydney (2012) [1].
Virions are dynamic structures reacting to environment with conformational changes, which
enable biologically relevant functions such as receptor/ligand binding [27]. Mutations in the virion
core, or neutralizing antibody binding to certain epitopes, can sterically block receptor binding site or
cause conformational change in distant epitopes impairing ligand interactions [27–29]. Some of the
highly variable blocking epitopes of NoV GII.4 are exposed on the surface of P2-domain (e.g., epitopes
A and D) while others, like epitope F, are buried and broadly conserved [25]. Epitope F is considered
a universal GII.4 blocking epitope, as monoclonal antibody specific to epitope F has been shown to
cross-block a panel of time-ordered GII.4 VLPs [30]. Amino acids 310, 316, 484, and 493 comprise “the
NERK motif”, which has been suggested to limit antibody access to epitope F [31].
In this study we investigated type-specific and cross-reactive humoral and cellular immune
responses induced in mice with the first (GII.4 1999, a 1995/96 US variant) and the latest (GII.4 Sydney,
2012) pandemic GII.4 variant VLPs. In addition, we studied the effect of an amino acid mutation in
the NERK motif on cross-blocking antibody responses. The results presented here add to the current
knowledge and understanding of cross-reactive immune responses induced in vivo by different variant
GII.4 VLPs.
2. Materials and Methods
2.1. NoV VLPs
Three different NoV GII.4 variant VLPs were used as immunogens and/or in vitro antigens in this
study. GII.4 1999 (original patient sequence isolated in 1999; it has one amino acid difference (aa 333)
to the VP1 sequence of the reference strain GII.4 1995/96 US, Genbank accession number AF080551)
and GII.4 2012 (accession number AFV08795.1) VLPs were produced in baculovirus-insect cell system
and purified as previously described by our laboratory [32–34]. GII.4 2006 variant VLPs (accession
number BAG70446) were produced by Icon Genetics Gmbh (Halle, Germany) [35] and were utilized in
analytical methods only. The epitope-engineered GII.4 2012 pFastBac1-vector with amino acid D310
substituted to N310 was ordered from GeneArt (Thermo Fisher Scientific, Waltham, MA, USA) and
expressed using the Bac-to-Bac Baculovirus Expression System (Invitrogen, Carlsbad, CA, USA) as
described before [32]. Mutant VLPs (referred as GII.4 2012 D310N) were produced and purified with
the same methodology as the wild-type VLPs. The identity, purity, and morphology [36,37] of the
VLPs were confirmed as described elsewhere [32,33,38].
2.2. Mouse Immunizations and Tissue Collections
Seven-week-old female BALB/c OlaHsd mice obtained from Envigo RMS BV (Horst,
the Netherlands) were immunized intramuscularly (IM) twice (weeks 0 and 3) with 10 µg of GII.4 1999
(5 mice) or GII.4 2012 VLPs (4 mice). Mice receiving carrier buffer only (phosphate buffered saline, PBS)
were used as negative controls (5 mice). Whole blood and lymphoid tissue were collected at the time
of euthanization on study week 5. For bone marrow-derived dendritic cell (BMDC) generation, femurs
and tibia were collected from naive control mice and the exterior tissues were sterilized with 70%
ethanol and kept on ice until bone marrow extraction (described in Section 2.6). Serum was separated by
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centrifugation and splenocyte suspensions of each mice were prepared according to earlier published
methods [38]. All procedures were authorized and performed in concordance with the guidelines by
the Finnish National Animal Experiment Board (permission number ESAVI/10800/04.10.07/2016).
2.3. IgG Titer and Avidity Assay
Antigen-specific and cross-reactive immunoglobulin G (IgG) responses in mice sera were
measured by enzyme-linked immunosorbent assay (ELISA) as described in detail elsewhere [32,38].
Individual sera were added by decreasing two-fold dilutions (IgG titer determination) or 1:100
dilution (avidity assay) on 96-well half-area polystyrene plates (Corning Inc., Corning, NY, USA)
coated overnight at 4 ◦C with NoV VLPs (1 µg/mL) and blocked for one hour at room temperature
(RT) with 2% skimmed milk in PBS/0.05%Tween. After serum incubation, the bound antibodies
were detected by goat anti-mouse IgG-HRP (dilution 1:6000, Sigma-Aldrich, Saint Louis, MO, USA)
reacting with o-phenylenediamine dihydrochloride (OPD)-substrate (30 min RT). All incubations were
performed at 37 ◦C for one hour unless otherwise stated. After stopping the substrate reaction with 2M
H2SO4 the optical density (OD) was measured at 490 nm (Victor2 1420; PerkinElmer, Waltham, MA,
USA). Each sample/dilution was assayed in duplicate wells and sample volumes were 50 µL/well.
The background signal from wells lacking serum (blank wells) was subtracted from all of the OD
readings at a plate. The cut-off value was calculated as mean OD + 3 × SD of negative control mice
sera at a given dilution. A sample resulting in an OD value above the set cut-off OD and at least 0.100
OD was considered positive. End-point antibody titers were defined as the highest dilution of serum
giving an OD above the set cut-off value. Geometric mean titers (GMTs) with 95% confidence intervals
(CIs) for each immunization group were counted from individual mice end-point titers.
Serum IgG avidity was measured by ELISA as described above, but after serum incubation the plates
were incubated twice (for 5 min for each treatment) with 8 M urea (Sigma-Aldrich) to elute low-avidity
antibodies [39]. The avidity index was calculated as (OD with urea/OD without urea) × 100%.
2.4. Carbohydrate Binding Assays
HBGA binding of mutated GII.4 2012 D310N VLPs in comparison to wild-type GII.4 2012 VLPs
was analyzed by using three different sources of HBGAs: human type A saliva [7,40], pig gastric mucin
(PGM, type III, Sigma-Aldrich) [41,42], and synthetic biotinylated HBGAs (Lewisa, Lewisb, H-type-1,
H-type-3, A-trimer, and B-trimer, Glycotech, Gaithersburg, MD, USA) [7,18]. Briefly, saliva (at dilution
1:3000, o/n 37 ◦C) or PGM (2.5 µg/mL, o/n RT) were used to coat half-area 96-well plates (Corning) and
synthetic biotinylated carbohydrates (2.5 µg/mL, 1 h RT) were used on precoated NeutrAvidin plates
(Pierce, Rockford, MI, USA). VLPs were added on the plates with final concentration of 0.1 µg/mL
for 1.5 h (saliva and PGM plates) or 0.4 µg/mL for 2 h (synthetic HBGA plates). The bound VLPs
were detected with human GII.4-positive serum following horseradish peroxidase (HRP)-conjugated
anti-human IgG secondary antibody (Novex, Invitrogen) incubation (1 h). After coating, saliva plates
were incubated at 37 ◦C, PGM plates at RT, and synthetic HBGA plates at 4 ◦C according to the
temperatures used in the original publications [18,40,41]. The plates were developed and stopped as
described in Section 2.3 for ELISA procedures. Positive reactivity is defined as a mean OD >0.2 after
background subtraction. Each sample was tested in 2–4 replicate wells and results are represented as
mean OD from parallel wells.
2.5. Blocking Assays
Blocking assay was used to measure antibodies that block binding of NoV VLPs to HBGAs
present in human saliva (type A) or PGM, or to synthetic biotinylated H-type-1 carbohydrate as
previously described [7,42]. NoV VLPs with final concentration of 0.1 µg/mL (saliva and PGM assays)
or 0.4 µg/mL (synthetic HBGA assays) were preincubated for 1 h at 37 ◦C in low binding tubes with
decreasing concentration of mice serum (starting at 1:100 serum dilution for homologous and 1:20
for cross-blocking assays). The pre-incubated VLP-serum mixtures were then added on saliva, PGM,
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or synthetic H-type-1 coated plates, and the bound VLPs were detected with human GII.4-positive
serum (for GII.4 1999 and GII.4 2012 VLP detection) or rabbit NoV-hyperimmune serum (for GII.4
2006 VLP detection) following the corresponding HRP-conjugated secondary antibody incubation.
The incubation times and temperatures were the same as described in Section 2.4 for VLP-binding
assays. The plates were developed, stopped, and measured as described in Section 2.3. Wells incubated
with VLPs lacking mouse sera were used to determine the maximum binding OD. The blocking index
(%) was calculated as 100%− [(OD wells with VLP− serum mix/OD maximum binding OD)× 100%].
The blocking titer 50 (BT50) value represents the highest serum dilution blocking 50% of the maximum
VLP binding. The results are expressed as the mean blocking indexes of individual mice or the mean
of replicas or repeated experiments if pooled group sera were used.
2.6. BMDC Generation and Pulsing
The method for generating mouse BMDCs was adapted from a published procedure [43] with
some modifications. After removing soft tissue, the femurs and the tibiae were cut from each end
with scalpel and flushed with ice cold PBS. The extracted bone marrows were passed through a
70-µm cell strainer (Becton-Dickinson, BD, Franklin Lakes, NJ, USA) and collected in complete
medium (CM, RPMI-1640 supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin,
50 µm 2-mercaptoethanol, 2 mm l-glutamine, and 10% fetal bovine serum (FBS), all purchased
from Sigma-Aldrich). The cell suspensions were centrifuged 300× g for 10 min and suspended
in CM containing 20 ng/mL recombinant mouse granulocyte-macrophage colony-stimulating factor
(GM-CSF, Abcam, Cambridge, UK). BM-cells were seeded at 1×106 cells/mL (10 mL per plate) in
non-treated 90 × 14.2-mm sterile petri dishes (VWR, Radnor, PA, US) and cultured at 37 ◦C, 5% CO2
for 8 days. Fresh CM with GM-CSF (5 mL/plate) was added on the dishes on days 4 and 7 and
the cells were harvested on day 8. The generated cells were surface stained with phycoerythrin
(PE)-conjugated anti-mouse CD11c and Horizon Viability Stain 780 (both from BD) and acquired using
BD FACSCanto II flow cytometer as described earlier [44] which confirmed the cells to be >90% CD11c+
cells. The BMDCs were frozen according to published procedure [45] in ice-cold CM containing 10%
DMSO (Sigma-Aldrich).
The BMDCs were thawed, washed twice (300× g, 10 min) and seeded 2×106 cells/mL in CM
in non-treated cell-culture 24-well plates (Corning Costar) for antigen pulsing. GII.4 1999, GII.4 2012
and GII.4 2006 VLPs were added to the cells at 100 µg/mL. Cells lacking pulsing antigen (un-pulsed
BMDCs) were used as a negative control. The cells were incubated (37 ◦C, 5% CO2) for 20–22 hours,
washed twice, and were used as antigen-presenting cells (APCs) in enzyme-linked immunospot
(ELISPOT) assay.
2.7. ELISPOT-Interferon Gamma (IFN-γ)
Homologous and cross-reactive T-cell responses were analyzed by quantification of IFN-γ
production from group-wise pooled mice splenocytes in response to VLP pulsed BMDCs by an
ELISPOT-IFN-γ assay [36,38]. Briefly, 96-well MultiScreen HTS-IP filter plates (Millipore, Billerica,
MA, USA) were coated overnight at 4 ◦C with anti-mouse IFN-γ (Mabtech Ab, Nacka Strand, Sweden).
After washing and blocking the plates with 10% FBS in CM (2–3 h RT), GII.4 1999, GII.4 2012, GII.4 2006
VLP pulsed or un-pulsed BMDCs (5000, 20,000, and 40,000 BMDCs/well) were added on plates.
Concanavalin A (ConA; Sigma-Aldrich) at 10 µg/ml was used as a positive control to stimulate IFN-γ
production from splenocytes. GII.4 1999 or GII.4 2012 VLP-immunized mice splenocytes were thawed,
washed, and added to the plates (0.2 × 106 cells/well) on top of BMDCs and the plates were incubated
for 20 h at 37 ◦C and 5% CO2. Thereafter, the cells were discarded and the plates were developed
with biotinylated anti-mouse IFN-γ monoclonal antibody (0.5 µg/mL in PBS/0.5% FBS, 2 h at RT)
and alkaline-phosphatase (ALP) conjugated streptavidin (1:1000, 1 h at RT) reacting with BCIP/NBT
substrate (all from Mabtech). After 12 minutes the color reaction was stopped with tap water. The spots
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were counted by an ImmunoSpot® automatic CTL analyzer (CTL-Europe GmbH, Bonn, Germany) and
the results are expressed as mean spot forming cells (SFCs) per 106 live splenocytes of replicate wells.
2.8. Statistics
The Kruskal–Wallis’ test was used to assess the statistical differences in antibody titers and avidity
indices between individual immunization groups. A statistically significant difference was defined as
a p-value of <0.05. Data were analyzed with IBM SPSS Statistics version 25.0 (SPSS Inc., Chicago, IL,
USA).
3. Results
3.1. NoV GII.4 Type-Specific and Cross-Reactive IgG Antibody Titers and Avidity
Immunized mice sera were tested using ELISA to quantify type-specific and cross-reactive
IgG antibodies against GII.4 1999, GII.4 2006, and GII.4 2012 VLPs (Figure 1a). GII.4 1999 and
GII.4 2012 immunizations resulted in equally high magnitudes (p = 0.264) of type-specific IgG
response, with GMTs of 102,400 and 86,100 (95% CI = 53,200–139,300), respectively. IgG responses
against homologous VLPs were significantly higher (p < 0.05) than cross-reactive responses induced
by heterologous antigen. GII.4 1999 VLP immunization induced significantly higher (p = 0.018)
cross-reactive IgG response against GII.4 2006 VLPs (GMT 25,600, 95% CI = 9600–69,900) than GII.4 2012
VLP immunization (GMT 3200, 95% CI = 1500–7000). When GII.4 1999 and GII.4 2012 cross-reactive
responses were compared against each other, GII.4 1999 immunization resulted in 2-fold higher GII.4
2012-specific titer (GMT 16,900, 95% CI = 5800–49,200) than GII.4 2012 immunization against GII.4 99
(GMT 8060, 95% CI = 3900–16,900) but the difference was not statistically significant (p = 0.15). Control
mice did not develop specific IgG response to any of the VLPs tested.
Figure 1. Titers and avidity of norovirus (NoV) type-specific and cross-reactive serum immunoglobulin
G (IgG) antibodies. Mice were immunized with GII.4 1999 (5 mice) and GII.4 2012 (4 mice) virus-like
particles (VLPs) and the immune sera was used in enzyme-linked immunosorbent assay (ELISA) to
determine the magnitude of IgG antibodies against homologous and heterologous NoV VLPs (a).
Serum of mice receiving phosphate buffered saline (PBS) (5 mice) was used as a negative control (Ctrl).
Shown are the geometric mean titers (GMTs) with 95% confidence intervals (error bars) counted from
individual mice end-point titers in each immunization group. The dashed line illustrates the cut-off
titer for samples considered positive. The avidity of IgG antibodies was measured from individual mice
sera against homologous and heterologous NoV VLPs (b) as described in the Material and Methods.
Horizontal lines in the box plots represent the medians, cross-symbols (×) represent the means, and
the boxes illustrate the interquartile range that contains 50% of values with whiskers extending to
the highest and lowest values. The antigen-specific antibody titers and the avidity indexes between
immunization groups were compared by the Kruskal–Wallis test and significant differences (p value
<0.05) are identified with an asterisk (*).
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Comparison of the avidity of type-specific and cross-reactive antibodies are shown in Figure 1b.
A remarkable difference was observed in the type-specific avidities elicited by GII.4 1999 and GII.4
2012 VLPs (Figure 1b). GII.4 1999 VLPs induced type-specific IgG antibodies with high avidity (mean
avidity index 85.7 ± 9%), whereas GII.4 2012 type-specific antibody avidity was poor (19.4 ± 10.7%).
As expected, the avidity of GII.4 1999 immune serum against heterologous VLPs was considerably
lower than type-specific avidity, but still at intermediate level (mean avidity indexes ranging from 30%
to 40%). GII.4 1999 VLP immunization elicited cross-reactive antibodies against GII.4 2006 VLPs with
significantly (p = 0.027) higher avidity than GII.4 2012 VLP immunization.
3.2. Blocking Antibody Responses
The ability of mouse immune sera to block homologous and heterologous VLPs binding to
HBGAs present in human saliva (type A) was tested in a blocking assay [7,40]. Both GII.4 1999 VLP
and GII.4 2012 VLP immunizations induced strong homologous blocking activity as mean serum
titers blocking at least 50% of VLP binding (BT50) were 1:800 for GII.4 1999 and 1:400 for GII.4
2012 (p = 0.079, Figure 2a). However, when GII.4 1999 and GII.2 2012 immune sera were used to
block heterologous VLPs binding, significant differences were observed in cross-blocking responses
(Figure 2b,c). GII.4 1999 VLP immunization (Figure 2b) elicited strong blocking activity against GII.4
2006 VLPs (BT50 = 1:640) while blocking against GII.4 2012 VLP binding was considerably lower (BT50
= 1:40). In contrast, GII.4 2012 immune sera (Figure 2c) blocked only GII.4 2006 VLP binding (BT50 =
1:40) at a significantly lower magnitude than GII.4 1999 immune sera (p = 0.036) and completely failed
to block GII.4 1999 binding. Control mice sera blocked all VLP binding <15% at the lowest serum
dilution (1:20).
Figure 2. Norovirus (NoV) type-specific and cross-reactive blocking antibodies. GII.4 1999 (5 mice)
or GII.4 2012 (4 mice) virus-like particle (VLP) immunized mice sera were individually diluted 2-fold
starting from 1:100 dilution and assayed for the blocking of homologous NoV VLPs binding to human
type A saliva (a). The cross-blocking activity of GII.4 1999 (b) and GII.4 2012 (c) VLP immunized mice
sera as well as control mice (Ctrl, 5 mice) was assayed against heterologous VLPs as 2-fold dilution
series starting from 1:20 dilution. The blocking index (percent) was calculated as follows: 100% × ((OD
wells with serum/OD wells without serum, maximum binding) × 100%). The symbols represent the
immunization group mean blocking indexes and the error bars represent the standard error between
individual mice. The horizontal dashed line represents the blocking titer 50% (BT50).
3.3. Morphology, Antigenicity, and HBGA-Binding Profile of Genetically Engineered GII.4 2012 D310N VLPs
The NERK motif (amino acids 310, 316, 484, and 493, respectively) is suggested to control antibody
access to epitope F, a putative universal blocking epitope in the GII.4 lineage [31]. We genetically
engineered GII.4 2012 VLP to revert amino acid 310 from D to N, as present in GII.4 1999 VLP.
The morphology of GII.4 2012 D310N VLPs was studied by electron microscopy, which confirmed that
the mutation did not affect mutated VLP integrity or morphology (Figure 3a) in comparison to wild
type GII.4 2012 VLPs (Figure 3b). The antigenicity of GII.4 2012 D310N VLPs was further investigated
using ELISA (Figure 3c). GII.4 1999 and GII.4 2012 VLP-immunized mice sera recognized wild-type
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(GII.4 2012) and mutated VLPs (GII.4 2012 D310N) with similar intensity (Figure 3c). HBGA binding
assay against human saliva A, PGM, and synthetic carbohydrates confirmed that mutation D310N did
not affect the ligand-binding abilities of the mutated VLPs (Figure 3d).
Figure 3. Morphology, antigenicity, and histo-blood group antigen (HBGA) binding of wild-type and
mutated GII.4 2012 virus-like particles (VLPs). Morphology of GII.4 2012 D310N (a) and GII.4 2012
(b) VLPs were examined by FEI Tecnai F12 electron microscope (Philips 487 Electron Optics, Holland)
after negative staining with 3% uranyl acetate pH 4.6. Mutated GII.4 2012 D310N VLPs and wild-type
GII.4 2012 VLPs were used as antigens with enzyme-linked immunosorbent assay (ELISA), reacting
with GII.4 2012, GII.4 1999, and control mice (ctrl) immune sera (c). VLPs were assayed for binding to
saliva type A, pig gastric mucin (PGM), and synthetic histo-blood group antigens as described in the
Materials and Methods (d). The symbols (c) and bars (d) illustrate the mean optical density (OD) at
490 nm of replicate wells (2–4) with standard errors. Lea, Lewisa; Leb, Lewisb; H-t-1, H-type-1; H-t-3,
H-type 3.
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3.4. Blocking Antibody Responses against Genetically Engineered GII.4 2012 D310N VLPs
To study the effect of amino acid 310 mutation on cross-blocking activity we used GII.4 1999
pooled immune sera to block wild-type GII.4 2012 and mutated GII.4 2012 D310N VLP binding to type
A saliva (Figure 4a), PGM (Figure 4b), and synthetic H-type-1 (Figure 4c). In saliva A and H-type-1
blocking assays BT50 increased 2-fold (from 1:40 to 1:80, Figure 4a and from 1:80 to 1:160, Figure 4c),
and in PGM blocking assay 4-fold (from 1:40 to 1:160, Figure 4b) in favor of the mutated VLPs. We also
investigated the sera blocking activity of GII.4 2012-immunized mice against GII.4 2012 D310N mutant
in synthetic H-type-1 blocking assay (Figure 4d) and no differences were observed in blocking of
wild-type and mutated GII.4 2012 VLPs.
Figure 4. The effect of amino acid (aa) 310 mutation within the NERK motif on cross-blocking activity.
Residue 310 of GII.4 2012 virus-like particles (VLPs) was substituted from D (aspartic acid) to N
(asparagine) to generate mutated GII.4 2012 D310N VLPs. Pooled GII.4 1999 immune serum was
assayed against wild-type and mutated GII.4 2012 VLPs in blocking assays utilizing human saliva
type A (a), pig gastric mucin (b), or synthetic H-type-1 (c) as the source of histo-blood group antigens
(HBGAs). Pooled GII.4 2012 immune serum was used to block the binding of GII.4 2012 and GII.4
2012 D310N VLPs to synthetic H-type-1 HBGAs (d). Control (Ctrl) mice sera illustrate the non-specific
blocking activity. The blocking index (percent) was calculated as follows: 100% × ((OD wells with
serum/OD wells without serum, maximum binding) × 100%). The symbols represent the mean
blocking indexes with standard errors between two repeated assays ((a) and (c)) or duplicate wells ((b)
and (d)) and the horizontal dashed line represents the blocking titer 50% (BT50).
3.5. T-Cell Responses
ELISPOT IFN-γ was used to investigate whether there are differences in the development
of homotypic or heterotypic T-cell immunity after GII.4 1999 and GII.4 2012 VLP immunization.
IFN-γ-producing cells were quantified from mice splenocytes in response to autologous BMDCs
pulsed with different NoV GII.4 VLPs. GII.4 1999 or GII.4 2012 VLP-immunized mice splenocytes
responded with similar intensity to GII.4 1999 (Figure 5a), GII.4 2012 (Figure 5b) and GII.4 2006
VLP (Figure 5c) pulsed BMDCs used as APCs in the ELISPOT. The highest IFN-γ production was
induced with GII.4 1999 VLP pulsed APCs followed by GII.4 2012 and GII.4 2006 VLP pulsed cells.
The magnitude of IFN-γ releasing cells increased with higher number of pulsed BMDCs. No significant
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IFN-γ production was detected when un-pulsed BMDCs were used as a negative control (Figure 5d).
All samples were tested in duplicate cells. Cell viability of the responding cells was similar in all assays
as controlled by Con A stimulation (data not shown). Background control (splenocytes in CM only)
resulted in <40 spots per 106 cells.
Figure 5. Norovirus (NoV) GII.4-specific T-cell responses. Group-wise pooled splenocytes of mice
immunized with GII.4 1999 virus-like particles (VLPs), GII.4 2012 VLPs, or PBS only (control mice) were
analyzed for interferon gamma (IFN-γ) production by an ELISPOT assay. Increasing number (legend)
of bone marrow-derived dendritic cells (BMDCs) pulsed with GII.4 1999 (a), GII.4 2012 (b), or GII.4
2006 (c) VLPs were used to stimulate the splenocytes of GII.4 1999 or GII.4 2012 VLP-immunized
mice. Un-pulsed BMDCs (d) served as a negative control. Mean IFN-γ spot-forming cells per 106 live
splenocytes of duplicate wells with standard deviations (error bars) are shown.
4. Discussion
An important issue in NoV VLP vaccine development is the antigenic diversity of NoV genotypes
and the evolution of the predominant GII.4 strain resulting in variants able to escape herd immunity [5].
A similar phenomenon drives the antigenic drift of influenza virus, and therefore influenza vaccine
must be reformulated on a yearly basis to match the circulating strains [16,46]. The NoV VLP vaccine
might also need to be reformulated every few years, or else cross-blocking epitopes could be induced
to generate broadly blocking antibodies that protect against a variety of NoV variants [28,30,47]. In our
earlier studies we have shown that ancestral GII.4 1999 VLPs tend to induce immune responses with
better cross-reactivity and higher quality than other NoV genotype VLPs [48–50]. To further investigate
GII.4 1999 VLP potential as a vaccine antigen, we compared the immune responses induced by GII.4
1999 VLPs and the most recent pandemic variant GII.4 2012 VLPs in mice. GII.4 2006 VLPs, representing
pandemic variant 2006a, were selected as a heterologous GII.4 antigen as the genetic distances to GII.4
1999 and GII.4 2012 variants were approximately equal (Figure 6a), with VP1 sequence amino acid
identities of 94.4% and 94.1%, respectively (Figure 6b).
Avidity of antibodies is considered to be an important surrogate of protective efficacy of several
vaccines [51,52] and high avidity enhances the cross-reactivity of antibodies by tolerating minor
variation in the target epitopes [53]. In this study, only GII.4 1999 VLPs were able to induce type-specific
antibodies with high avidity, whereas GII.4 2012 VLPs induced only antibodies with very low avidity.
B cells that take up an antigen can either mature into extrafollicular plasmablasts secreting low-affinity
antibodies or enter into germinal center (GC) where affinity maturation takes place with the help of
follicular DCs and T-cells [54]. GII.4 1999 and GII.4 2012 VLPs may be differently uptaken or presented
in GC affecting affinity maturation, but further studies are needed to confirm this notion. However,
based on the results obtained here, antibody avidity cannot be considered as a single correlate of
a strong blocking activity, as GII.4 2012 VLPs induced poor avidity antibodies but still conferred
homologous blocking similarly to GII.4 1999 serum. Instead, high antiserum avidity may enhance
the cross-neutralization ability as broadly neutralizing antiviral antibodies are usually detected in
recurrent/chronic infections or after repeated vaccinations [55].
We observed that GII.4 1999 immune serum had blocking activity against GII.4 2012 but not vice
versa. The finding is in concordance with our earlier results where GII.4 1999 immune serum was able
to block the VLP binding of another contemporary variant (GII.4 NO) to HBGAs whereas GII.4 NO
Viruses 2019, 11, 91 10 of 15
immune serum completely lacked blocking activity against GII.4 1999 [48]. There might be several
reasons as to why an ancestral GII.4 variant would induce blocking antibodies against a contemporary
GII.4 variant but not vice versa. One potential explanation could be the surface structure of these
VLPs. X-ray crystallography with murine NoVs has revealed that P-domains can be either in “open”
or “closed” conformation [28] and some NoV VLPs are found in more epitope-accessible form than
others [25], giving reason to speculate as to whether such structural differences affect the immune
responses generated in vivo. Hypothetically, better epitope-accessibility promotes the development
of broadly blocking antibodies as conserved blocking epitopes tend to locate in more occluded than
exposed parts of the NoV capsid [25,47] and thus are not easily reached by B cell receptors. GII.4 2012
VLPs might be in a less epitope-accessible form than GII.4 1999 VLPs, explaining the different levels of
humoral cross-reactivity induced. Possibly the evolution drives NoV to alter its structure to a more
closed one to sterically protect the conserved epitopes, and therefore ancestral strains might be more
suitable for the generation of cross-reactive immunity. However, additional studies are needed to
evaluate the conformational differences and the epitope-accessibility between GII.4 variants.
GII.4 1999 immune serum cross-blocked GII.4 2006 VLP binding similarly to homologous VLP,
whereas GII.4 2012 serum cross-blocking activity against GII.4 2006 VLPs was significantly lower. Other
investigators have bioinformatically identified blocking epitopes A-F and shown that evolution in these
epitopes, especially in evolving epitopes A and D, might have resulted GII.4 variants to escape from
herd immunity [23,26,31]. Alignment of amino acid sequences of VLPs used in this study according to
epitopes A–F and the NERK motif revealed that GII.4 1999 and GII.4 2012, together with GII.4 2006
variants, share the same number (10/22) of identical amino acids in these epitopes (Figure 6c). Epitope
A holds 2/7 identical residues between GII.4 1999 and GII.4 2006, whereas none of the amino acids in
the epitope A are shared between GII.4 2012 and GII.4 2006 variants. In contrast, GII.4 1999 and 2006
share only 1/4 amino acids in blocking epitope D, whereas 3/4 identical residues are found between
GII.4 2012 and GII.4 2006 variants. Therefore, it is likely that the number of identical amino acids in
the blocking epitopes A–F does not solely explain the better GII.4 2006 VLP cross-blocking potency of
GII.4 1999 immune serum. However, some amino acids, such as 294 and 373 in the epitope A [23,26]
and 310 in the NERK motif [31], shared between GII.4 1999 and GII.4 2006 VLPs might have greater
impact on cross-blocking responses than other amino acids. In addition to blocking epitopes discussed
here, other epitopes affecting the blocking responses have been published [28,29] and there could be
other yet undiscovered regions impacting the cross-blocking responses.
Broadly conserved epitopes are often occluded in the capsid and can be shielded by the virion
via selected motifs regulating the exposition of these epitopes [27]. Epitope F in NoV GII.4 is an
occluded, broadly conserved GII.4 blocking epitope, and the NERK motif is a potential conformational
determinant regulating antibody access to epitope F [28,31]. The NERK motif has remained unchanged
among pandemic GII.4 variants from 1995 to 2006 and thereafter evolved from SERK (GII.4 NO 2009)
to DERK (GII.4 Sydney 2012) by a single amino acid substitution at position 310 (Figure 6c). Both GII.4
1999 and GII.4 2006 share asparagine (N) at position 310 and we reasoned that residue 310 might
explain the great blocking activity observed between GII.4 1999 sera and GII.4 2006 VLPs. As a result,
amino acid 310 substitution from D to N in GII.4 2012 VLP capsid improved GII.4 1999 immune
serum blocking potency 2–4-fold. This moderate improvement in the cross-blocking potency might
indicate that asparagine at position 310 limits the antibody access to blocking epitope less than aspartic
acid (D) at the same position. Others have exchanged residue 310 between GII.4 NO and GII.4 2012
VLPs and the effect on blocking activity of monoclonal antibody targeted to blocking epitope F was
investigated [31]. As a result, mutated GII.4 NO (S310D) VLP blocking decreased (at max 4.1-fold) and
in turn mutated GII.4 2012 (D310S) blocking increased (at max 3.2-fold) suggesting that serine (S) at
position 310 indicates better access to the conserved blocking epitope F [31]. The difference with respect
to our study was that we used polyclonal mouse serum instead of a monoclonal antibody generated
against the single particular epitope. In contrast to cross-blocking activity, the D310N mutation did not
have any effect on the homologous blocking activity of GII.4 2012 immune sera. This indicates that
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NERK motif-“guarded” F epitope is important specifically in cross-blocking responses, which supports
earlier findings by others [30,31].
Figure 6. Phylogenetic tree and the amino acid (aa) sequences within blocking epitopes A–F and the
NERK motif based on the VP1 amino acid sequences of norovirus (NoV) GII.4 strains. The tree illustrates
the phylogenetic analysis of seven pandemic GII.4 NoV major capsid protein VP1 aa sequences with
the GII.4 variant VP1 sequences used as virus-like particles (VLPs) in this study (boldface) (a). The tree
was inferred by neighbor-joining method with a bootstrap of 1000 by using MegaX. The percentages
of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates)
are shown next to the branches. The evolutionary distances were computed using the p-distance
method and the scale bar shows the genetic distance, expressed as amino acid substitutions per site.
ClustalW VP1 amino acid sequence alignment of GII.4 1999, GII.4 2006, and GII.4 2012 variants used
as VLPs in this study (b). Asterisk (*) indicates fully conserved amino acids, colon (:) indicates
conservation between groups of strongly similar properties and period (.) indicates conservation
between groups of weakly similar properties. Amino acid sequences of blockade epitopes A to F and
the NERK motif [21,25,31] in GII.4 variants (c). Identical amino acids between GII.4 1999 and GII.4
2006 are shaded and bolded. Identical amino acids between GII.4 2012 and GII.4 2006 are shaded and
underlined. *Motif regulating antibody access to the epitope F [31]. **Critical key residues of blockade
epitope F [25]. ***Mutated VLP used in this study. Genbank accession numbers to VP1 amino acid
sequences of published GII.4 strains are as follows: AF080551 (1995/96 US), AY502023 (Farmington
Hills 2002), DQ078794 (Hunter 2004), EF126963 (Yerseke 2006a), BAG70446 (2006), EF126965 (Den Haag
2006b), GU445325 (New Orleans 2009), AFV08795.1 (Sydney 2012).
The role of T-cell immunity in protection against NoV infection and disease is not well known but
it might have a role in the generation of heterologous immunity [56,57]. We and others have previously
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identified conserved NoV-specific CD4+ and CD8+ T-cell epitopes in mice [36,49,58]. Here, we were
interested to see if the different potentials of GII.4 1999 and GII.4 2012 VLPs to induce cross-reactive
antibodies were true also for T-cell responses. However, we did not detect a considerable difference
in T-cell responses against any of the VLPs between GII.4 1999- and GII.4 2012-immunized mice.
The results indicate that in the light of cross-reactivity, T-cell responses are quite distinct from B-cell
responses and support earlier findings that T-cell responses are targeted to buried, broadly conserved
epitopes in the NoV capsid [36,49,56,58]. However, variation in the magnitude of the IFN-γ SFC
between VLPs used for pulsing was detected. The highest number of IFN-γ-producing cells were
detected with BMDCs pulsed with GII.4 1999 VLPs (regardless of the immunization), which suggests
that GII.4 1999 VLPs could be uptaken and/or processed most efficiently by APCs.
We have previously proposed a candidate NoV VLP vaccine including GII.4 1999 and GI.3
VLPs [12]. The results of this study showed that GII.4 1999 VLP immunization induced higher-affinity
antibodies with improved cross-reactive and cross-blocking properties in comparison to GII.4 2012
VLPs. The ability to elicit broad cross-reactive immunity is a key element of a successful NoV vaccine.
We suggest that VLP structure (e.g., epitope accessibility), avidity of the antibodies and T-cell immunity
might all play important role in heterologous NoV immunity and therefore should be considered in
vaccine VLP selection. Based on the results of this study, and our earlier findings [48–50], the ancestor
GII.4 1999 VLPs have an intrinsic property of inducing antibodies with broad cross-reactivity and thus
are good candidates for an NoV VLP vaccine.
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